



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 30, 2022

Philip Astley-Sparke  
Chief Executive Officer  
Replimune Group, Inc.  
500 Unicorn Park Drive  
3rd Floor  
Woburn MA 01801

**Re: Replimune Group, Inc.**  
**Registration Statement on Form S-3**  
**Filed June 23, 2022**  
**File No. 333-265805**

Dear Mr. Astley-Sparke:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Timothy Corbett